Notice2024-31702
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production Activity; Sanofi US Services Inc.; (Pharmaceutical Products); Ridgefield, New Jersey
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 6, 2025
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 3 (Monday, January 6, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 3 (Monday, January 6, 2025)]
[Notices]
[Page 596]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-31702]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-62-2024]
Foreign-Trade Zone (FTZ) 49, Notification of Proposed Production
Activity; Sanofi US Services Inc.; (Pharmaceutical Products);
Ridgefield, New Jersey
Sanofi US Services Inc. submitted a notification of proposed
production activity to the FTZ Board (the Board) for its facilities in
Ridgefield, New Jersey within FTZ 49. The notification conforming to
the requirements of the Board's regulations (15 CFR 400.22) was
received on December 18, 2024.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished product is Beyfortus[supreg] (Nirsevimab)--
dosage form vaccine (duty-free).
The proposed foreign-status materials/components include
Beyfortus[supreg] (Nirsevimab monoclonal antibody active pharmaceutical
ingredient)--unmixed and mixed drug substance (duty-free).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#7e180a043e0a0c1f1a1b50191108"><span class="__cf_email__" data-cfemail="395f4d43794d4b585d5c175e564f">[email protected]</span></a>. The closing period for their receipt is February 18,
2025.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#eda9848c8388c3ab84839b889fad999f8c8988c38a829b"><span class="__cf_email__" data-cfemail="c581aca4aba0eb83acabb3a0b785b1b7a4a1a0eba2aab3">[email protected]</span></a>.
Dated: December 31, 2024.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2024-31702 Filed 1-3-25; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 6, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.